

Filterlex Medical raises \$3M in Series A Financing

16 July 2019 | News

Filterlex won the best innovation award at the EuroPCR 2019 conference in Paris and was awarded \$200,000 prize by the Jon DeHaan Foundation



Filterlex Medical is a medical device start-up company based in Israel, developing an innovative embolic protection device (CAPTIS) for reducing the risk of stroke and other complications during catheter-based structural heart procedures.

The company recently completed a series A round of financing, raising a total of \$3M. CAPTIS, which provides an exciting breakthrough for TAVR patients, won best innovation award at the PCR 2019 innovation competition in Paris and was awarded a grant of \$200,000 by the Jon DeHaan foundation.

During catheter-based, left-heart procedures such as TAVI, embolic particles are often released to the blood flow. Particles migration to the brain may cause a spectrum of neurological deficiencies, from cognitive impairment to debilitating stroke. Emboli released to distal organs may result in acute kidney injury and ischemia.

Sigal Eli, founder, inventor and CEO of Filterlex Medical said, "We are very honored and proud to receive this prestigious award by the Jon DeHaan Foundation at the EuroPCR 2019. Leading interventional cardiologists and top industry executives selected CAPTIS for the Best Innovation Award. Out of 80 competing projects, only 6 innovations were selected for the final competition – of which our project, presented by Prof. Giora Weisz (Co-founder). The international recognition provided, will allow us to present our product to the international cardiologists and we believe it will become must have best-in-class device to benefit patients undergoing left-heart procedures such as TAVR."

The CAPTIS device is a next-generation full-body embolic protection device, easily and intuitively deployed and retrieved. The device is securely positioned in the aorta, protects its surface while facilitating a seamless TAVI procedure. Its distinctive, triple action design provides a full-body embolic protection by deflecting, capturing and removing embolic particles. Uniquely, it requires no additional arterial access and does not interfere with the procedure workflow.